AZN vs CORT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AZN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and CORT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and CORT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026.

Full CORT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
• CORT drivers: Cushing's / hypercortisolism growth runway; Relacorilant as the next-generation successor.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For CORT, revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AZN if you believe its drivers more; CORT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and CORT guides.

AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 14.6 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 core EPS near $10.05 rising to about $11.34 in 2027. After falling about 9.5% in 2026, the forward multiple sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation now reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Q3 2026 results arrive October 30, with consensus revenue near $16.0 billion. Figures are approximate and tied to the asOf date; confirm live numbers before acting.

CORT. Corcept swung from a Q1 2026 net loss of roughly $31 million, driven by Lifyorli launch spending, to a ~$42 million profit in Q2 on record revenue, so the trailing P/E above 200x mostly reflects depressed recent earnings. On forward numbers the picture is different: analysts expect about $4.41 of EPS in 2027, which puts the stock near 25x, a growth-and-optionality premium that leaves little room for a slower launch. Gross margin near 98% means incremental revenue drops through quickly once launch costs level off.

Headline figures (approximate, October 2026): AZN shows revenue (ttm) About $61.4 billion; Q2 2026 revenue about $15.4 billion, up roughly 6% year over year, net income (ttm) About $10.5 billion, a net margin near 17%, with gross margin near 82%, eps Q2 2026 EPS $1.32 vs about $1.25 expected; trailing reported EPS about $6.69, p/e About 25x trailing reported earnings, about 14.6x forward; CORT shows revenue (ttm) ~$831M; Q2 2026 +31.7% YoY, fy2025 revenue ~$761M, fy2026 revenue guidance (raised earlier in 2026) ~$950M to $1.05B; consensus ~$1.15B, net income (ttm) ~$54M (EPS ~$0.45).

AZN and CORT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and CORT exposure against your real portfolio. It is not an investment adviser.